1.0Laos Alliance Pharmaceutical Grouphttps://alliancepharmagroup.com/lorich600338<blockquote class="wp-embedded-content" data-secret="U2nMzPw8Wx"><a href="https://alliancepharmagroup.com/lo/ສິນຄ້າ/alidabrafenib/">ALIDABRAFENIB</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://alliancepharmagroup.com/lo/ສິນຄ້າ/alidabrafenib/embed/#?secret=U2nMzPw8Wx" width="600" height="338" title="“ALIDABRAFENIB” — Laos Alliance Pharmaceutical Group" data-secret="U2nMzPw8Wx" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script> /*! This file is auto-generated */ !function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document); //# sourceURL=https://alliancepharmagroup.com/wp-includes/js/wp-embed.min.js </script>https://alliancepharmagroup.com/wp-content/uploads/2024/12/Alidabrafenib.png12801280COMPOSITION Dabrafenib mesylate........................................75mg INDICATION Dabrafenib is a kinase inhibitor indicated. It can be taken alone or in combination with trametinib. Used to treat unresectable or metastatic melanoma patients with BRAF V600E mutation positivity. Used for postoperative adjuvant treatment of BRAF V600E mutation positive melanoma. Used to treat metastatic non-small cell lung cancer caused by BRAF V600E mutation. PACKAGING: • 30 tablets/bottle. Reg No: 10 L 1222/24 Download ALIDABRAFENIB Drug Registration Certificate ... Read More